Day: March 23, 2023

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Written by Customer Service on March 23, 2023. Posted in Public Companies.

Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapyThis potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapyCOPENHAGEN, Denmark, March 23, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies today announces that it has developed a new proprietary AI platform technology ObsERV™ to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy. ObsERV™, Evaxion’s new proprietary AI platform technology, identifies patient-specific virus targets, so-called ERVs...

Auctions of mortgage covered bonds for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3®

Written by Customer Service on March 23, 2023. Posted in Public Companies.

To Nasdaq Copenhagen A/S Executive Board Lersø Parkalle 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 23 March 2023 Company Announcement number 22/2023 Auctions of mortgage covered bonds for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3® Realkredit Danmark will hold auctions on SDRO’s for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3® as of 1 July 2023. The auctions will be held on 24 – 25 May 2023. Realkredit Danmark will open two new mortgage covered bonds (SDRO’s) to put on the auctions for the refinancing of RD Cibor6® and RD Euribor3®, respectively. The underlying bond to RD Cibor6® will be used for new loan offers at a later stage whereas the underlying bond to RD Euribor3® will be used for new loan offers immediately after the refinancing has taken place. At the auctions,...

Nano Dimension’s Chairman and CEO Answers Questions on the Company’s Products, Materials and variety of Technologies

Written by Customer Service on March 23, 2023. Posted in Public Companies.

Insights Into the Important Advancements Driving Industry 4.0 Digital Manufacturing Solutions Waltham, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, released a video in which Yoav Stern, Chairman and Chief Executive Officer, responds to questions from shareholders about the Company’s products and technologies. Yoav Stern sheds light on the newest advancements that are underpinning the Company’s progress in providing new digital manufacturing solutions that are realizing Industry 4.0 capabilities for mechanical and electronic Additive Manufacturing products, materials and applications. Click here to watch...

Vantage Drilling International Reports Fourth Quarter and Full-Year 2022 Results

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

HOUSTON, March 23, 2023 (GLOBE NEWSWIRE) — Vantage Drilling International (“Vantage” or the “Company”) reported a net loss attributable to controlling interest of approximately $16.4 million, or $1.25 per diluted share, for the three months ended December 31, 2022, based on the weighted average shares outstanding, as compared to a net loss attributable to controlling interest of $23.5 million, or $1.79 per diluted share, for the three months ended December 31, 2021. For the year ended December 31, 2022, Vantage reported a net loss attributable to controlling interest of approximately $3.4 million or $0.26 per diluted share, as compared to a net loss attributable to controlling interest of $110.1 million or $8.40 per diluted share for the year ended December 31, 2021. As of December 31, 2022, Vantage had approximately...

Society Pass (Nasdaq: SOPA) Reports Compelling 4Q 2022 and FY 2022 Financial Results; Recognises 530% Year on Year Revenue Growth for 4Q 2022; Recognises 984% Year on Year Revenue Growth for FY 2022; Forecasts Path to Profitability in 2023

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

New York, NY, March 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Society Pass Inc. (Nasdaq: SOPA) (“SoPa”), Southeast Asia (SEA)’s next generation, data-driven, loyalty, fintech and e-commerce ecosystem, today announces unaudited financial results for fourth quarter ended 31 December 2021 and audited financial results for the full year ended 31 December 2022 and a filing of its 2022 Form 10-K with the Securities and Exchange Commission (SEC). Click Here (on SEC website) to view 2022 Form 10-K filing. Summary Points:• 4Q 2022 revenues grew 530% year on year (from $419,062 in 4Q 2021 to $2,641,137 in 4Q 2022). • Full year 2022 revenues grew 984% year on year (from $519,885 in full year 2021 to $5,635,553 in full year 2022). • 4Q 2022 gross profit grew to $673,969 from -$27,328 in 4Q 2021. • Full year 2022 gross profit grew to...

Green Shift Signs Purchase Agreement to Acquire 25% Interest in Pampa Litio S.A., a Private Hard Rock Lithium Exploration Company in Argentina

Written by Customer Service on March 23, 2023. Posted in Mergers And Acquisitions.

TORONTO, March 23, 2023 (GLOBE NEWSWIRE) — Green Shift Commodities Ltd. (TSXV: GCOM), (“Green Shift”, “GCOM” or the “Company”) is pleased to announce that it has signed a definitive agreement (the “Agreement”) with New Peak Metals Limited (“New Peak”) (ASX: NPM), to acquire (the “Acquisition”) a 25% interest in Pampa Litio S.A. (“Pampa Litio”). Pampa Litio is a private Argentinean company exploring for hard rock spodumene bearing pegmatites in the Pampean Ranges of Central Argentina. Pursuant to the Agreement dated March 22, 2023, GCOM has agreed to pay CAD$150,000 in cash and to issue 535,714 common shares of GCOM (the “Common Shares”) as consideration for New Peak’s 25% interest in Pampa Litio; provided that, in certain circumstances, the Company has agreed to pay CAD$75,000 in cash in lieu of the issuance of the Common Shares....

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors – – Dosed first patient in Phase 1 clinical trial evaluating IL-12 INDUKINE WTX-330 in patients with advanced or metastatic solid tumors or lymphoma – – Nominated WTX-712, a conditionally active IL-21 INDUKINE molecule targeting oncology indications; preclinical data to be presented at AACR Annual Meeting 2023 in Orlando, Florida – – Updated cash runway guidance to fund cash flow requirements through at least 4Q 2024 – WATERTOWN, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate...

FactSet Reports Results for Second Quarter 2023

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

Q2 GAAP revenues of $515.1 million, up 19.5% from Q2 2022 Organic Q2 ASV plus professional services of $1.9 billion, up 9.1% year over year Q2 GAAP operating margin of 32.9%, up 430 bps year over year, and adjusted operating margin of 37.0%, up 330 bps over the prior year Q2 GAAP diluted EPS of $3.38, up 19.0% from the prior year, and adjusted diluted EPS of $3.80, up 16.2% year over year FactSet is updating fiscal 2023 guidance, with expected ASV + professional services growth of 7% – 9%, adjusted operating margin of 34%-35%, and adjusted diluted EPS growth of 8% – 11%.NORWALK, Conn., March 23, 2023 (GLOBE NEWSWIRE) — FactSet (“FactSet” or the “Company”) (NYSE: FDS) (NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, today announced results for its second...

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

Validive® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next WeekCamsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m2) WILMETTE, Ill., March 23, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and full-year 2022 financial results and summarized recent developments. Recent Developments Validive – International Phase 2b/3 Trial, Interim Go/No-go Analysis on Track for End of Next WeekThe VOICE trial, in planning for a potential positive go/no-go outcome from the interim analysis, continues to enroll patients in the Phase 3 portion...

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)

Written by Customer Service on March 23, 2023. Posted in Public Companies.

– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continuous, once-daily dosing regimen and synergistic efficacy to treat cancers driven by KRAS mutations – If successful, the combination of investigational therapy BBP-398 and OPDIVO has the potential to address the serious unmet need for patients with KRAS-mutated non-small cell lung cancer (NSCLC) and other advanced solid tumors with KRAS mutations PALO ALTO, Calif., March 23, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc., (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient with non-small cell lung cancer (NSCLC) has been dosed in its...

Day: March 23, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice